US Revenue
$222M
+43% YoY
Highest ever quarterly US revenue, driven by differentiated portfolio including Lanreotide and base business growth.
CIPLA
Healthcare
20 Jul 2023
Cipla Ltd — Q1 FY24
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY). EBITDA margin expanded to 23.6%, aided by favorable mix and operational efficiencies. PAT stood at INR 996 crore (15.7% of sales). The US complex portfolio, including Lanreotide (18% market share) and stabilized Albuterol, powered growth, while India's chronic share rose to 60%. Management raised full-year EBITDA margin guidance to ~23% (from 22% earlier). Key pipeline catalysts include Symbicort filing by year-end, 4-5 peptide launches over two years, and de-risking of Advair and Abraxane. Risks include US FDA classification for Indore facility and potential pricing pressure in the US generics market.
सिप्ला ने पहली तिमाही में शानदार प्रदर्शन किया। कंपनी की कमाई पिछले साल से 18% बढ़कर 6,329 करोड़ रुपये हो गई। भारत में बिक्री 12% और अमेरिका में 43% बढ़ी। कंपनी का मुनाफा 996 करोड़ रुपये रहा। अमेरिका में लैनरियोटाइड दवा की बाजार हिस्सेदारी 18% है। भारत में पुरानी बीमारियों की दवाओं की हिस्सेदारी 60% हो गई। कंपनी ने पूरे साल के लिए मुनाफा मार्जिन का लक्ष्य 23% रखा है। आने वाले समय में नई दवाएं लॉन्च होंगी। जोखिम में अमेरिकी नियामक की जांच और दवाओं की कीमतों में कमी शामिल है।
Key Numbers
India Chronic Share
60%
+2pp YoY
Chronic therapies now 60% of India branded prescription revenue, up from 58% last year.
Foracort Growth
27%
+27% YoY
Leading inhaler brand Foracort grew 27% in Q1, among fastest in top 10 IPM brands.
Lanreotide Market Share
18%
N/A
Lanreotide market share improved to 18% as per MAT May 2023, up from prior levels.
Management Guidance
Full-year EBITDA margin target of ~23%
Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets.
Management guidance marginsSymbicort filing by end of FY24
Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023.
Management guidance growth4-5 peptide launches in next two years
Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period.
Management guidance growthAdvair launch within 12 months via de-risking
Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.
Management guidance growthKey Risks
US FDA classification for Indore facility pending
Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.
high · management_commentaryAlbuterol recall and market share loss
Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.
medium · management_commentaryPotential pricing pressure in US generics
While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.
medium · analyst_questionGoa facility re-inspection uncertainty
Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.
high · management_commentaryNotable Quotes
Our differentiated portfolio in U.S. continues to deliver strong growth for the franchise. The business yet again achieved its highest sales in the quarter by realizing a revenue of $222 million, growing by a strong 43% over the last year.
We expect the full year EBITDA to be trending towards 23% for the year.
I think our base level will be somewhere in the range of 210-215. I mean, what I meant by 210-215 was what we will be reporting, broadly going forward, quarter by quarter.
Frequently Asked Questions
What was Cipla's revenue in Q1 FY24?
Cipla reported revenue of ₹6,329 Cr in Q1 FY24, representing a +18% change compared to the same quarter last year.
What guidance did Cipla management give for FY25?
Full-year EBITDA margin target of ~23%: Management raised FY24 EBITDA margin guidance to approximately 23%, up from earlier 22% guidance, driven by strong Q1 performance and confidence across markets. Symbicort filing by end of FY24: Cipla expects to file generic Symbicort (respiratory product) by the end of calendar year 2023. 4-5 peptide launches in next two years: Cipla plans to launch 4-5 peptide products over the next two years, with a couple of new peptide filings in the same period. Advair launch within 12 months via de-risking: Generic Advair is being transferred to an in-house facility; launch expected within 12 months with no incremental generic competition anticipated.
What are the key risks for Cipla in FY25?
Key risks include US FDA classification for Indore facility pending — Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.; Albuterol recall and market share loss — Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.; Potential pricing pressure in US generics — While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.; Goa facility re-inspection uncertainty — Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products..
Did Cipla meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Cipla Q1 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.